Avid Bioservices (CDMO) Appoints Esther M. Alegria to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Avid Bioservices (CDMO) PT Raised to $29 at Stephens
July 1, 2021 6:26 AM EDTStephens analyst Jacob Johnson raised the price target on Avid Bioservices (NASDAQ: CDMO) to $29.00 (from $26.00) while maintaining a Overweight rating.... More
Avid Bioservices (CDMO) PT Raised to $29 at Craig-Hallum
June 30, 2021 8:49 AM EDTCraig-Hallum analyst Matthew Hewitt raised the price target on Avid Bioservices (NASDAQ: CDMO) to $29.00 (from $21.00) while maintaining a Buy rating.
The analyst commented, "With the stock hitting 52-week highs, expectations were high going into Avids Q4 earnings report, but in our... More
Avid Bioservices (CDMO) PT Raised to $27 at RBC Capital
June 30, 2021 6:12 AM EDTRBC Capital analyst Sean Dodge raised the price target on Avid Bioservices (NASDAQ: CDMO) to $27.00 (from $21.00) while maintaining a Outperform rating.... More
Avid Bioservices (CDMO) PT Raised to $28 at KeyBanc
June 30, 2021 4:40 AM EDTKeyBanc analyst Paul Knight raised the price target on Avid Bioservices (NASDAQ: CDMO) to $28.00 (from $22.00) while maintaining a Overweight rating.... More
Avid Bioservices (CDMO) Reports Q4 Loss of $0.04/sh
June 29, 2021 4:11 PM EDTAvid Bioservices (NASDAQ: CDMO) reported Q4 EPS of ($0.04), versus ($0.11) reported last year. Revenue for the quarter came in at $27.6 million versus the consensus estimate of $21.6 million.
GUIDANCE:
Avid Bioservices sees FY2021 revenue of $115-117 million, versus the consensus of $89.9... More
